| scholarly article | Q13442814 |
| P356 | DOI | 10.1093/JAC/DKQ375 |
| P953 | full work available at URL | http://jac.oxfordjournals.org/cgi/content/abstract/65/12/2530 |
| http://academic.oup.com/jac/article-pdf/65/12/2530/16862354/dkq375.pdf | ||
| P698 | PubMed publication ID | 20940181 |
| P5875 | ResearchGate publication ID | 47403526 |
| P2093 | author name string | Harald Labischinski | |
| Will Stubbings | |||
| Peter Heisig | |||
| Anke Heisig | |||
| Nadine-C Emrich | |||
| P2860 | cites work | Emerging mechanisms of fluoroquinolone resistance | Q24644842 |
| Plasmid-mediated quinolone resistance: a multifaceted threat | Q24645356 | ||
| qnrB, another plasmid-mediated gene for quinolone resistance | Q34510366 | ||
| Characterization of fluoroquinolone-resistant mutants of escherichia coli selected in vitro | Q35821472 | ||
| New plasmid-mediated fluoroquinolone efflux pump, QepA, found in an Escherichia coli clinical isolate | Q36094929 | ||
| Coexistence of qnrB4 and qnrS1 in a clinical strain of Klebsiella pneumoniae | Q42646339 | ||
| Fluoroquinolone-modifying enzyme: a new adaptation of a common aminoglycoside acetyltransferase | Q46862305 | ||
| Identification of the plasmid-borne quinolone resistance gene qnrS in Salmonella enterica serovar Infantis | Q50080463 | ||
| The effects of NorA inhibition on the activities of levofloxacin, ciprofloxacin and norfloxacin against two genetically related strains of Staphylococcus aureus in an in-vitro infection model. | Q54076880 | ||
| Quinolone resistance from a transferable plasmid. | Q54143628 | ||
| Plasmid-mediated quinolone resistance | Q82262149 | ||
| P433 | issue | 12 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Escherichia coli | Q25419 |
| finafloxacin | Q21011229 | ||
| P304 | page(s) | 2530-2533 | |
| P577 | publication date | 2010-10-12 | |
| P1433 | published in | Journal of Antimicrobial Chemotherapy | Q6294770 |
| P1476 | title | Antibacterial activity of finafloxacin under different pH conditions against isogenic strains of Escherichia coli expressing combinations of defined mechanisms of fluoroquinolone resistance | |
| P478 | volume | 65 |
| Q89551956 | Antibiotic Delivery Strategies to Treat Skin Infections When Innate Antimicrobial Defense Fails |
| Q30249262 | Antibiotics in the clinical pipeline at the end of 2015. |
| Q34185670 | Antibiotics in the clinical pipeline in 2011. |
| Q38133967 | Antibiotics in the clinical pipeline in 2013. |
| Q41878231 | Commonality among fluoroquinolone-resistant sequence type ST131 extraintestinal Escherichia coli isolates from humans and companion animals in Australia |
| Q33843665 | Demonstrating the Protective Efficacy of the Novel Fluoroquinolone Finafloxacin against an Inhalational Exposure to Burkholderia pseudomallei |
| Q50020716 | Early clinical assessment of the antimicrobial activity of finafloxacin compared to ciprofloxacin in sub-sets of microbiologically characterized isolates |
| Q50020710 | Efficacy and Safety of Finafloxacin versus Ciprofloxacin in the Treatment of Complicated Urinary Tract Infections: An Explorative Randomized Phase II Clinical Study |
| Q38526001 | Finafloxacin for the treatment of urinary tract infections. |
| Q53755551 | Finafloxacin overcomes Burkholderia pseudomallei efflux-mediated fluoroquinolone resistance. |
| Q38391019 | Finafloxacin: first global approval |
| Q36290512 | High Efficacy of Finafloxacin on Helicobacter pylori Isolates at pH 5.0 Compared with That of Other Fluoroquinolones |
| Q38283158 | In vitro spectrum of activity of finafloxacin, a novel, pH-activated fluoroquinolone, under standard and acidic conditions |
| Q34375204 | Investigational antimicrobial agents of 2013. |
| Q33601794 | Pharmacodynamics of Finafloxacin, Ciprofloxacin, and Levofloxacin in Serum and Urine against TEM- and SHV-Type Extended-Spectrum-β-Lactamase-Producing Enterobacteriaceae Isolates from Patients with Urinary Tract Infections |
| Q36683409 | Pipeline of Known Chemical Classes of Antibiotics |
| Q48232629 | Population pharmacokinetics of finafloxacin in healthy volunteers and patients with complicated urinary tract infections. |
| Q38233471 | Renaissance of antibiotics against difficult infections: Focus on oritavancin and new ketolides and quinolones |
| Q38194624 | The effects of pH on wound healing, biofilms, and antimicrobial efficacy. |
| Q44970812 | The efficacy of silver dressings and antibiotics on MRSA and MSSA isolated from burn patients |
| Q36683661 | Uncomplicated Urinary Tract Infections and Antibiotic Resistance-Epidemiological and Mechanistic Aspects |
Search more.